Investing in medtech starts with one very important truth: it’s all about time and money.
While founders talk enthusiastically about “changing lives” and “revolutionizing care,” investors think in slightly different (and much more pragmatic) terms: How long will it take and how much will it cost?
Every factor in medtech product development—technology, regulatory pathways, clinical trials, reimbursement, and commercialization—eventually rolls up to these two KPIs. For Class III implantables, that might mean 7–10 years and hundreds of millions of dollars. For lower-risk devices (Class I and II), timelines and budgets shrink, but the principle doesn’t, because for potential investors, the bigger the risk class, the bigger the price tag—and the bigger the potential reward. This is where good medtech due diligence can really pay off.
What Investors Should Look For (Beyond a Good Pitch Deck)
Whether you’re investing $10M or $100M, the criteria are remarkably consistent:
- A big unmet clinical need : Venture capitalists like markets with billion-dollar potential. If the device solves a niche, low-value problem…proceed with caution.
- A stage-appropriate, domain-experienced team: Even brilliant clinicians and engineers often lack commercialization experience. And as anyone who’s ever brought a product to market will tell you, commercialization—not regulatory clearance—is the steepest part of the journey.
- Strong technology differentiation: A device must be meaningfully better than existing options—or dramatically easier to use. Ideally both.
- Realistic regulatory and clinical strategy: For Class III devices, clinical trials can be the most expensive phase—sometimes more than commercialization itself. And thanks to Europe’s new MDR unpredictability, even Class I and II teams are shifting to “U.S. first” market strategy.
- A path to reimbursement: Earlier than ever, investors expect a reimbursement roadmap. No payment = no adoption.
- A credible exit pathway: No one invests just to admire the device forever.
Founders vs. Investors: Why Risk Looks Different From Each Side of the Table
Founders tend to see risk as a straight line—once you get through development and regulatory hurdles, it’s smooth sailing. Investors, on the other hand, see risk as a snowball rolling downhill and picking up complexity.
Startups often assume FDA clearance means the market will immediately adopt the device – a classic case of being too in love with your own science. The reality? The market may or may NOT adopt your device.
Why? Because your investment thesis may look great on paper but could have nothing to do with what’s happening in the real world. Here are some examples:
1. Your device may solve a problem that doesn’t exist in your target market
A skin cancer screening tool worked beautifully in Europe, where dermatology wait times can be a year, but flopped in the U.S., where access is easy and the device wasn’t reimbursable.
2. Your target clinicians may not have the right skillset
A minimally invasive cardiac ablation system failed because it required a skill set closer to electrophysiology—but was marketed to general surgeons. (Spoiler: this does not end well.)
3.When manufacturing breaks the business case
One product relied on radioactive isotopes sourced from disassembled Russian bombs. Great idea, until there are no more disassembled Russian bombs.
You just can’t make this stuff up.
Commercialization is the step where many devices stumble, even low-risk ones. In fact, some lower-risk devices can take years longer to scale than their high-risk counterparts – it all depends on the problem and the solution. Yet another strong argument for really robust medtech due diligence.
For devices addressing a known problem with a known solution, such as improvements to feeding tubes, adoption can happen relatively quickly—typically within one to two years. When the problem is known but the solution is new or unfamiliar, like technologies aimed at reducing IV medication errors, adoption generally takes longer, often three to five years. And for innovations that tackle an unknown problem with an unknown solution—for example, safer methods of nasogastric tube placement—the journey can be significantly longer. One such company spent more than 15 years moving from early research to influencing global clinical practice, reflecting a lengthy and complex adoption timeline.
The Red Flags Every Investor Should Watch For
Here are some big medtech due diligence potholes to avoid unless you really enjoy pain – and losing money. If any of these do pop up, tread as carefully as you would walking through a mine field:
Regulatory red flags often surface early in due diligence and can signal significant downstream risk. These include product claims that aren’t supported by the device’s actual clearance, misalignment between the stated intended use and available reimbursement pathways, and missing or incomplete regulatory documentation. Another major warning sign is unauthorized market expansion—such as selling in Europe without obtaining the appropriate CE marking—which can expose a company to compliance issues and enforcement actions.
Quality system red flags can be equally damaging, particularly when a company has a weak or nonexistent QMS, leaving essential processes unsupported or undocumented. In some cases, the opposite problem appears: an overbuilt electronic QMS that drains resources and adds unnecessary complexity without improving compliance. Another common issue is ineffective design controls—systems that look good on paper but fail to genuinely guide, document, or manage the design process—creating gaps that can jeopardize both safety and regulatory approval.
Manufacturing red flags can pose serious risks to scalability and compliance. One of the most common issues is when the tooling is owned by the contract manufacturer rather than the company itself, which can create costly barriers if the relationship ends. Problems also arise when manufacturers are not properly registered with the FDA, putting the entire supply chain at risk. Additionally, producing devices in non–free trade countries while planning to sell to the U.S. government can create compliance roadblocks that many teams don’t anticipate until it’s too late.
So…Should You Invest?
Absolutely—medtech is filled with extraordinary founders solving meaningful problems. But successful investing requires clear-eyed due diligence, realistic expectations, and a willingness to test assumptions rather than fall in love with the pitch.
You can’t plan for an exit, but you can plan for the milestones that make exits possible. And even the best devices fail without thoughtful commercialization.
The good news? With the right frameworks (and the right questions), your medtech due diligence can flag both the winners and the landmines long before your money hits the wire.
For readers interested in exploring this topic further, the following may be helpful:
-
The full video presentation: Due Diligence for Investors
-
Video: Concept to Commercialization: A Roadmap for Successful Medtech Innovation
Each is designed to build on the concepts discussed here—whether you’re looking for a quick perspective or a more detailed, implementation-focused view.
